Abstract Rationale Poor adherence to biologic therapies is associated with worse treatment outcomes in patients with asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), indicating the importance of managing underlying inflammation. Biologic therapies for the treatment of asthma and/or CRSwNP have revolutionized treatment over the last decade; with dosing frequency as a key differentiator between biologic treatments. Frequent dosing of current biologics may impact initiation and adherence in clinical practice; as such, a longer dosing interval may potentially improve patient outcomes. We surveyed patients with asthma and/or CRSwNP to assess preferences regarding dosing schedule and barriers to biologic use. Methods An online, cross-sectional, anonymous survey was conducted (July 23-August 16, 2025) in the US. Eligible survey participants were aged ≥18 years, diagnosed with and treated for moderate-to-severe asthma (MA-SA; with ≥2 exacerbations requiring treatment/hospital visit in past 12 months) and/or CRSwNP (have had or discussed surgery for CRSwNP with healthcare provider). Participants were stratified as biologic-experienced (current/past biologic use) or biologic-naïve. Demographics, treatment history, perceived barriers to biologic treatment, and dosing preferences were collected. Responses were summarized using descriptive statistics. Results Eighty patients (n = 52 asthma, n = 28 CRSwNP) completed the US survey. 100% of biologic-naïve asthma participants (n = 42) and CRSwNP participants (n = 9) expressed interest in a treatment requiring only twice-yearly administration, assuming all other attributes were equivalent to current treatments. Notably, 96% of biologic-experienced (current) participants (n = 26) indicated they would likely switch to a twice-yearly dosed biologic if offered. Likewise, 95% of all participants (n = 80) said they would prefer a biologic treatment that only requires twice-yearly dosing. Dosing schedule/frequency was identified as a barrier to biologic therapy for 23% of biologic-naïve participants and biologic-experienced participants who had previously switched biologic (n = 70). Additionally, 52% of biologic-experienced participants (n = 29) reported dosing schedule as a factor that influenced their adherence. Conclusion Participants with MA-SA and/or CRSwNP showed overwhelmingly positive interest in a biologic requiring only twice-yearly dosing. Nearly all biologic-experienced participants would prefer or switch to such therapy if available. Frequent injection schedules were perceived as a barrier to initiating or switching biologic therapy by about one-quarter of participants. These findings highlight that a twice-yearly dosed biologic is highly desirable to participants, which may impact positively on biologic uptake, long-term adherence, and potentially patient outcomes, mitigating an important real-world treatment hurdle in asthma and CRSwNP. This abstract is funded by: GSK (212675)
Deb et al. (2026) studied this question.